Navigating Growth: Procalcitonin (PCT) Assay Market Positioned for US$ 512.9 Million Valuation by 2033

Comments ยท 958 Views

The sector's resilience and potential are underscored by the forecasted valuation, indicating a robust outlook for the coming decade.

With a projected market value of US$ 280.6 million in 2023 and an expected CAGR of 6.2% over the forecast period, the global procalcitonin (PCT) assay market is expected to develop significantly, reaching a valuation of US$ 512.9 million by 2033.

One of the key drivers for this growth is the increasing incidence of lung cancer, emphasizing the need for accurate and early diagnosis. The PCT assay market has experienced remarkable expansion owing to heightened awareness about the critical role of early and precise diagnosis in bacterial infections.

Unleash the extraordinary. Claim your sample for unmatched efficiency:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17617

The Procalcitonin (PCT) assay market focuses on diagnostic tests that measure procalcitonin levels in the bloodstream. Procalcitonin is a precursor protein to the hormone calcitonin, and its production is triggered by bacterial infections. The market is committed to improving patient care by offering advanced diagnostic solutions for bacterial infections.

As the Procalcitonin (PCT) Assay Market continues to advance, it is anticipated to play a pivotal role in enhancing the early detection and management of bacterial infections, contributing to better healthcare outcomes.

Key Takeaways:

1.     Market Growth:The market is expected to experience substantial growth, with a projected valuation of $512.9 million by 2033, driven by a CAGR of 6.2% during the forecast period.

2.     Lung Cancer Incidences:The increasing incidence of lung cancer is a significant driver for market growth, underlining the need for early and accurate diagnosis of bacterial infections.

3.     Awareness and Importance:Growing awareness about the importance of early and precise diagnosis of bacterial infections has contributed to the market’s expansion.

4.     PCT Assay Definition:The market revolves around diagnostic tests that measure procalcitonin levels in the bloodstream. Procalcitonin is a precursor protein produced in response to bacterial infections.

5.     Enhanced Diagnostic Solutions:The PCT assay market is committed to offering advanced diagnostic solutions for bacterial infections, with the goal of improving patient care.

6.     Early Detection:PCT assays play a pivotal role in the early detection of bacterial infections, allowing for prompt treatment and better healthcare outcomes.

7.     Clinical Utility:Procalcitonin assays are valuable tools for clinicians to assess the presence and severity of bacterial infections, guiding treatment decisions.

8.     Patient Care:The focus on precise diagnosis and early intervention is aligned with providing optimal patient care and improving healthcare outcomes.

9.     Innovative Diagnostics:The market’s growth reflects ongoing innovations in diagnostic technologies and their impact on the field of bacterial infection detection.

10. Global Impact:The Procalcitonin (PCT) Assay Market contributes to the global efforts to enhance healthcare by improving the accuracy and timeliness of bacterial infection diagnosis.

Key Players:

  • J. Mitra & Co. Pvt. Ltd.
  • Thermo Fisher Scientific Inc.
  • Elabscience Biotechnology Inc.
  • CUSABIO TECHNOLOGY LLC
  • Wuhan Fine Biotech Co., Ltd.
  • Company ABclonal, Inc.
  • Nanjing Vazyme Biotech Co.,Ltd.
  • RayBiotech Life, Inc.
  • Hipro Biotechnology Co.,Ltd.
  • Vitrosens Biotechnology
  • bioMérieux SA
  • ELK Biotechnology CO.,Ltd.
  • Immuno-Biological Laboratories, Inc.
  • BISAF
  • Roche Diagnostics

Key Developments:

  • In November 2020, Roche and bioMérieux announced a collaboration to improve antibiotic stewardship by developing and providing PCT assays on Roche’s cobas platforms.
  • In February 2020, bioMérieux received FDA clearance for the Vidas BRAHMS PCT assay, which is an automated immunoassay platform for measuring PCT levels.

Key Segmentation:

By Sample Type:

  • Serum
  • Plasma
  • Cell Culture Medium
  • Other Biological Fluids

By Product:

  • Test Kits
    • Procalcitonin ELISA test kits
    • Procalcitonin CLIA kits
    • PCT Immunochromatography KITS
    • PCT Rapid Test Kit
  • Analyzer & Instruments
  • Consumables

By Purpose:

  • Clinical Use
  • Research Use Only

By End User:

  • Hospital
  • Specialty Clinics
  • Academic and Research Institute
  • Diagnostics Laboratories

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East & Africa

 

 

With a projected market value of US$ 280.6 million in 2023 and an expected CAGR of 6.2% over the forecast period, the global procalcitonin (PCT) assay market is expected to develop significantly, reaching a valuation of US$ 512.9 million by 2033.

One of the key drivers for this growth is the increasing incidence of lung cancer, emphasizing the need for accurate and early diagnosis. The PCT assay market has experienced remarkable expansion owing to heightened awareness about the critical role of early and precise diagnosis in bacterial infections.

Unleash the extraordinary. Claim your sample for unmatched efficiency:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17617

The Procalcitonin (PCT) assay market focuses on diagnostic tests that measure procalcitonin levels in the bloodstream. Procalcitonin is a precursor protein to the hormone calcitonin, and its production is triggered by bacterial infections. The market is committed to improving patient care by offering advanced diagnostic solutions for bacterial infections.

As the Procalcitonin (PCT) Assay Market continues to advance, it is anticipated to play a pivotal role in enhancing the early detection and management of bacterial infections, contributing to better healthcare outcomes.

Key Takeaways:

1.     Market Growth:The market is expected to experience substantial growth, with a projected valuation of $512.9 million by 2033, driven by a CAGR of 6.2% during the forecast period.

2.     Lung Cancer Incidences:The increasing incidence of lung cancer is a significant driver for market growth, underlining the need for early and accurate diagnosis of bacterial infections.

3.     Awareness and Importance:Growing awareness about the importance of early and precise diagnosis of bacterial infections has contributed to the market’s expansion.

4.     PCT Assay Definition:The market revolves around diagnostic tests that measure procalcitonin levels in the bloodstream. Procalcitonin is a precursor protein produced in response to bacterial infections.

5.     Enhanced Diagnostic Solutions:The PCT assay market is committed to offering advanced diagnostic solutions for bacterial infections, with the goal of improving patient care.

6.     Early Detection:PCT assays play a pivotal role in the early detection of bacterial infections, allowing for prompt treatment and better healthcare outcomes.

7.     Clinical Utility:Procalcitonin assays are valuable tools for clinicians to assess the presence and severity of bacterial infections, guiding treatment decisions.

8.     Patient Care:The focus on precise diagnosis and early intervention is aligned with providing optimal patient care and improving healthcare outcomes.

9.     Innovative Diagnostics:The market’s growth reflects ongoing innovations in diagnostic technologies and their impact on the field of bacterial infection detection.

10. Global Impact:The Procalcitonin (PCT) Assay Market contributes to the global efforts to enhance healthcare by improving the accuracy and timeliness of bacterial infection diagnosis.

Key Players:

  • J. Mitra & Co. Pvt. Ltd.
  • Thermo Fisher Scientific Inc.
  • Elabscience Biotechnology Inc.
  • CUSABIO TECHNOLOGY LLC
  • Wuhan Fine Biotech Co., Ltd.
  • Company ABclonal, Inc.
  • Nanjing Vazyme Biotech Co.,Ltd.
  • RayBiotech Life, Inc.
  • Hipro Biotechnology Co.,Ltd.
  • Vitrosens Biotechnology
  • bioMérieux SA
  • ELK Biotechnology CO.,Ltd.
  • Immuno-Biological Laboratories, Inc.
  • BISAF
  • Roche Diagnostics

Key Developments:

  • In November 2020, Roche and bioMérieux announced a collaboration to improve antibiotic stewardship by developing and providing PCT assays on Roche’s cobas platforms.
  • In February 2020, bioMérieux received FDA clearance for the Vidas BRAHMS PCT assay, which is an automated immunoassay platform for measuring PCT levels.

Key Segmentation:

By Sample Type:

  • Serum
  • Plasma
  • Cell Culture Medium
  • Other Biological Fluids

By Product:

  • Test Kits
    • Procalcitonin ELISA test kits
    • Procalcitonin CLIA kits
    • PCT Immunochromatography KITS
    • PCT Rapid Test Kit
  • Analyzer & Instruments
  • Consumables

By Purpose:

  • Clinical Use
  • Research Use Only

By End User:

  • Hospital
  • Specialty Clinics
  • Academic and Research Institute
  • Diagnostics Laboratories

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East & Africa

 

 

Comments